Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Rating of “Buy” by Brokerages
Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten analysts that are covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokerages […]
More Stories
House Passes DHS Funding Bill Amid Shutdown
By Jackson Richman and Nathan Worcester WASHINGTON—The House of Representatives passed a bill to fund the Department of Homeland Security...
Unemployment Claims Signal Labor Market Stabilization Ahead of Jobs Report
By Andrew Moran The number of Americans filing applications for state unemployment benefits was flat ahead of tomorrow’s highly anticipated...
More Than 20 States Sue Over Trump’s New Global Tariffs
By Matthew Vadum More than 20 states filed a lawsuit on March 5 in federal court against President Donald Trump’s...
At Least 9 Vessels Attacked in Gulf Since Iran War Began
By Owen Evans At least nine vessels have come under attack since the U.S.–Israel military operation against Iran began on...
Hegseth Signs Joint Declaration to Boost Counter-Cartel Efforts in Western Hemisphere
By Ryan Morgan DORAL, Florida.—U.S. Secretary of War Pete Hegseth joined military officials from across Latin America and the Caribbean...
Typical US Homeowners Stay 12 Years in Their Homes—20 Years in Los Angeles
By Mary Prenon U.S. homeowners stayed in their houses for about 12 years as of 2025—the longest median time since...